Unicycive Therapeutics, Inc. – NASDAQ:UNCY
Founder-led company
Unicycive Therapeutics stock price today
$4.09
+3.29
+411.51%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Unicycive Therapeutics stock price monthly change
+61.65%
month
Unicycive Therapeutics stock price quarterly change
+61.65%
quarter
Unicycive Therapeutics stock price yearly change
+12.06%
year
Unicycive Therapeutics key metrics
Market Cap | 69.56M |
Enterprise value | 31.47M |
P/E | -1.9 |
EV/Sales | 33.09 |
EV/EBITDA | -1.25 |
Price/Sales | 33.40 |
Price/Book | -68.17 |
PEG ratio | 0.02 |
EPS | -1.2 |
Revenue | N/A |
EBITDA | -25.09M |
Income | -37.00M |
Revenue Q/Q | -100% |
Revenue Y/Y | -116.66% |
Profit margin | -2653.1% |
Oper. margin | -2652.47% |
Gross margin | 0% |
EBIT margin | -2652.47% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeUnicycive Therapeutics stock price history
Unicycive Therapeutics stock forecast
Unicycive Therapeutics financial statements
| Jun 2023 | 0 | -3.83M | |
|---|---|---|---|
| Sep 2023 | 0 | -4.40M | |
| Dec 2023 | -271K | -7.79M | 2877.49% |
| Mar 2024 | 0 | -20.96M |
| Sep 2025 | 11M | -3.82M | -34.76% |
|---|---|---|---|
| Oct 2025 | 14.5M | 116.36K | 0.8% |
| Dec 2025 | 11M | -1.63M | -14.83% |
| Dec 2025 | 29.36M | 2.56M | 8.72% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -0.13 | -0.13 |
|---|---|---|
| 2024-03-28 | -0.18 | -0.16 |
| 2024-05-13 | -0.18 | -0.27 |
| Jun 2023 | 22883000 | 16.05M | 70.15% |
|---|---|---|---|
| Sep 2023 | 19442000 | 16.00M | 82.34% |
| Dec 2023 | 14191000 | 18M | 126.84% |
| Mar 2024 | 52385000 | 76.84M | 146.69% |
| Jun 2023 | -5.50M | -12K | 0 |
|---|---|---|---|
| Sep 2023 | -4.42M | 0 | -51K |
| Dec 2023 | -4.43M | 0 | -205K |
| Mar 2024 | -6.45M | -6K | 45.69M |
Unicycive Therapeutics alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 14 |
| Jun 2024 | 14 |
| Jul 2024 | 14 |
Unicycive Therapeutics other data
0.20%
-5.08%
of UNCY is owned by hedge funds
30.82K
-764.42K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 15000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | JERMASEK DOUGLAS officer: EVP of Corporate Strat.. | Common Stock | 104,612 | $0.49 | $51,260 | ||
Option | JERMASEK DOUGLAS officer: EVP of Corporate Strat.. | Warrant (right to buy) | 115,275 | $0.74 | $85,304 | ||
Option | JERMASEK DOUGLAS officer: EVP of Corporate Strat.. | Warrant (right to buy | 79,252 | $0.54 | $42,796 | ||
Option | JERMASEK DOUGLAS officer: EVP of Corporate Strat.. | Warrant (right to buy) | 72,047 | $0.59 | $42,508 | ||
Option | JERMASEK DOUGLAS officer: EVP of Corporate Strat.. | Series A-1 Convertible Preferred Stock | 50 | $0.49 | $25 | ||
Option | GUPTA PRAMOD officer: EVP, Pha.. | Warrant (right to buy) | 46,110 | $0.74 | $34,121 | ||
Option | GUPTA PRAMOD officer: EVP, Pha.. | Common Stock | 41,845 | $0.49 | $20,504 | ||
Option | GUPTA PRAMOD officer: EVP, Pha.. | Warrant (right to buy | 31,700 | $0.54 | $17,118 | ||
Option | GUPTA PRAMOD officer: EVP, Pha.. | Warrant (right to buy) | 28,818 | $0.59 | $17,003 | ||
Option | GUPTA PRAMOD officer: EVP, Pha.. | Series A-1 Convertible Preferred Stock | 20 | $0.49 | $10 |
| Patent |
|---|
Application Filling date: 16 Mar 2020 Issue date: 25 Aug 2022 |
Application Filling date: 30 Nov 2021 Issue date: 17 Mar 2022 |
Application Filling date: 6 Jun 2019 Issue date: 26 Mar 2020 |
-
What's the price of Unicycive Therapeutics stock today?
One share of Unicycive Therapeutics stock can currently be purchased for approximately $4.09.
-
When is Unicycive Therapeutics's next earnings date?
Unfortunately, Unicycive Therapeutics's (UNCY) next earnings date is currently unknown.
-
Does Unicycive Therapeutics pay dividends?
No, Unicycive Therapeutics does not pay dividends.
-
How much money does Unicycive Therapeutics make?
Unicycive Therapeutics has a market capitalization of 69.56M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 29.02% to 675K US dollars. Unicycive Therapeutics made a loss 30.54M US dollars in net income (profit) last year or -$0.27 on an earnings per share basis.
-
What is Unicycive Therapeutics's stock symbol?
Unicycive Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "UNCY".
-
What is Unicycive Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Unicycive Therapeutics?
Shares of Unicycive Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Unicycive Therapeutics's key executives?
Unicycive Therapeutics's management team includes the following people:
- Dr. Shalabh K. Gupta M.D., MPA Founder, Chairman, Chief Executive Officer & Pres(age: 52, pay: $643,500)
- Dr. Pramod Gupta Ph.D. Executive Vice President of Pharmaceutical & Bus. Operations(age: 64, pay: $60,000)
-
Is Unicycive Therapeutics founder-led company?
Yes, Unicycive Therapeutics is a company led by its founder Dr. Shalabh K. Gupta M.D., MPA.
-
How many employees does Unicycive Therapeutics have?
As Jul 2024, Unicycive Therapeutics employs 14 workers, which is 17% more then previous quarter.
-
When Unicycive Therapeutics went public?
Unicycive Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 12 Jul 2021.
-
What is Unicycive Therapeutics's official website?
The official website for Unicycive Therapeutics is unicycive.com.
-
Where are Unicycive Therapeutics's headquarters?
Unicycive Therapeutics is headquartered at 4300 El Camino Real, Los Altos, CA.
-
How can i contact Unicycive Therapeutics?
Unicycive Therapeutics's mailing address is 4300 El Camino Real, Los Altos, CA and company can be reached via phone at +65 03514495.
Unicycive Therapeutics company profile:
Unicycive Therapeutics, Inc.
unicycive.comExchange:
NASDAQ
Full time employees:
14
Industry:
Biotechnology
Sector:
Healthcare
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
4300 El Camino Real
Los Altos, CA 94022
Los Altos, CA 94022
CIK: 0001766140
ISIN: US90466Y1038
CUSIP: 90466Y103
